Menu
POTENTIAL DEAL DETAILS
| Stock | Tesaro, Inc. | Symbol | TSRO |
| Date Announced | 11/16/2018 | Source | Bloomberg |
| Type | News Report |
| Date of Confirmation: | 12/03/2018 | Price at Confirmation: | $73.68 |
| Potential Profit: | 110.76% | Annualized Profit: | 2377.98% |
Tesaro Inc., (TSRO) a drugmaker whose shares tumbled this month after disclosing disappointing clinical trial results, is exploring a sale, according to people familiar with the matter.
Update(s):
December 03, 2018: GlaxoSmithKline plc (GSK) and TESARO Inc (TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK (GSK) will acquire TESARO (TSRO), an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion).
Disclaimer: Our intent with this section of the website is to present potential deals that appear to be in the pipeline. These potential deals are ones where i) the company has indicated that it is "seeking strategic alternatives", ii) there has been an unsolicited bid for a company as mentioned in a press release by the company or iii) news about the deal has been published by a leading news organization like The Wall Street Journal, The New York Times, Bloomberg, Financial Times, The Washington Post, Reuters and The Associated Press. As best as possible we will try to avoid baseless rumors. There is a high probability that many of these potential deals may not materialize and if they do, the terms of the deal may be different from what was initially reported. Please do your own due diligence before buying or selling any securities mentioned on this website. We do not warrant the completeness or accuracy of the content or data provided.